SCHEMBL3382824

SCHEMBL3382824

Cc1ccc(C(CN)C(=O)O)c(C)c1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
GRM1 Q13255 2/20 0.42
CYP1A2 P05177 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
CACNA2D1 P54289 3/20 0.39
CACNA1B Q00975 3/20 0.39
CACNB1 Q02641 3/20 0.39
CACNA1C Q13936 2/20 0.39
CACNA1G O43497 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
TAAR1 Q96RJ0 1/20 0.38
MAPK1 P28482 1/20 0.38
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
ROCK2 O75116 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL510474 0.84 SRC (0.44) SRCMEN1KMT2AGRM1CYP1A2
SCHEMBL6207353 0.81 SRC (0.46) SRCMEN1KMT2AGRM1CYP1A2
SCHEMBL5156728 0.79 PDE5A (0.41) SRCMEN1KMT2AGRM1CYP1A2
SCHEMBL3383530 0.79 ROCK2 (0.49) MEN1KMT2ACYP1A2SMN1; SMN2ROCK2
SCHEMBL638662 0.77 GABBR2 (0.49) MEN1KMT2ACYP1A2CACNA2D1CACNA1B
SCHEMBL25894342 0.77 GRM1 (0.69) SRCMEN1KMT2AGRM1CYP1A2
SCHEMBL10999528 0.76 PDE5A (0.45) SRCMEN1KMT2ATDP1SMN1; SMN2
SCHEMBL4986412 0.76 ALDH1A1 (0.39) SRCMEN1KMT2AGRM1CYP1A2
SCHEMBL7864024 0.76 MEN1 (0.44) SRCMEN1KMT2AGRM1CYP1A2
SCHEMBL8960497 0.74 TRPA1 (0.44) SRCMEN1KMT2AGRM1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415480-B2 Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor MERCK SERONO SA (CH) 2013-04-09 US disclosed
EP-1487442-B1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR MERCK SERONO SA (CH) 2010-12-01 EP disclosed
US-20090215749-A9 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR LABORATOIRES SERONO S.A. (CH) 2009-08-27 US disclosed
US-20080255094-A1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR LABORATOIRES SERONO S.A. (CH) 2008-10-16 US disclosed
US-20050215605-A1 Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor MERCK SERONO SA (CH) 2005-09-29 US disclosed
EP-1487442-A1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR Applied Research Systems ARS Holding N.V. (AN) 2004-12-22 EP disclosed
WO-2003082278-A1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2003-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215749-A9 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR PTGER4, PTGER2, PTGER1 SRC 4533/4885MEN1 4868/4885KMT2A 2053/4885
US-20080255094-A1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR PTGER4, PTGER2, PTGER1 SRC 4533/4885MEN1 4868/4885KMT2A 2053/4885
US-20050215605-A1 Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor TBXA2R, CNR2, PTGDR SRC 4124/4885MEN1 4706/4885KMT2A 3544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.